<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ADENOSINE</span><br/>(a-den'o-sin)<br/><span class="topboxtradename">Adenocard, </span><span class="topboxtradename">Adenoscan<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">antiarrhythmic</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>3 mg/mL in 2, 5, and 30 mL vials</p>
<h1><a name="action">Actions</a></h1>
<p>Slows conduction through the atrioventricular (AV) and sinoatrial (SA) nodes. Can interrupt the reentry pathways through the
         AV node. Depresses left ventricular function, but effect is transient due to short half-life.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Restores normal sinus rhythm in patients with paroxysmal supraventricular tachycardia.</p>
<h1><a name="uses">Uses</a></h1>
<p>Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT) including PSVT associated with accessory bypass
         tracts (Wolff-Parkinson-White syndrome). "Chemical" thallium stress test.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Afterload-reducing agent in low-output states; to prevent graft occlusion following aortocoronary bypass surgery; to produce
         controlled hypotension during cerebral aneurysm surgery.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>AV block, preexisting second- and third-degree heart block or sick sinus rhythm without pacemaker, since a heart block may
         result. Also contraindicated in atrial flutter, atrial fibrillation, and ventricular tachycardia because the drug is ineffective.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Asthmatics, pregnancy (category C), hepatic and renal failure.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Supraventricular Tachycardia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 6 mg rapid IV bolus (over 12 s); may repeat in 12 min with 12 mg IV push, 2 times (total of 3 doses with max:
               12 mg dose)<br/><span class="rdage">Neonate/</span><span class="rdage">Infant/</span><span class="rdage">Child:</span> <span class="rdroute">IV</span> 0.05 mg/kg; may increase dose by 0.05 mg/kg q2 min (max: 0.25 mg/kg/dose or 12 mg/dose)<br/><br/><span class="indicationtitle">Stress Thallium Test</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 140 mcg/kg/min <small>x</small> 6 min (max: 0.84 mg/kg total dose)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>Make sure solution is clear at time of use. </li>
<li> Discard unused portion (contains no preservatives).</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> No dilution is required.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span>  Administer directly into vein as a rapid bolus over 12 s. If given by IV line, administer as proximally as possible,
                  and follow with a rapid saline flush.  
               </p>
<ul>
<li>
                     						Note: If high-level block develops after one dose, do not repeat dose.
                     					
                  </li>
</ul>
</td>
</tr>
</table>
<ul>
<li>Store at room temperature 15°30° C (59°86° F). Do not refrigerate, as crystallization may
            occur. If crystals do form, dissolve by warming to room temperature.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, lightheadedness, dizziness, tingling in arms (from IV infusion), apprehension, blurred vision, burning sensation
      (from IV infusion). <span class="typehead">CV:</span>
<span class="speceff-common">Transient facial flushing,</span> sweating, palpitations, chest pain, atrial fibrillation or flutter. <span class="typehead"> Respiratory:</span>  Shortness of breath, transient <span class="speceff-common">dyspnea,</span> chest pressure. <span class="typehead">GI:</span> Nausea, metallic taste, tightness in throat. <span class="typehead">Other:</span> Irritability in children. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Dipyridamole</b> can potentiate the effects of adenosine; <b>theophylline</b> will block the electrophysiologic effects of adenosine; <b>carbamazepine</b> may increase risk of heart block. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapid uptake by erythrocytes and vascular endothelial cells after IV administration. <span class="typehead">Onset:</span>  2030 s. <span class="typehead">Metabolism:</span> Rapid uptake into cells; degraded by deamination to inosine, hypoxanthine, and adenosine monophosphate. <span class="typehead">Elimination:</span> Route of elimination unknown. <span class="typehead">Half-Life:</span> 10 s. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of bronchospasm in asthma patients. Notify physician immediately.</li>
<li>Use a hemodynamic monitoring system during administration; monitor BP and heart rate and rhythm continuously for several minutes
            after administration.
         </li>
<li>
            							Note: Adverse effects are generally self-limiting due to short half-life (10 s).
            						
         </li>
<li>
            							Note: At the time of conversion to normal sinus rhythm, PVCs, PACs, sinus bradycardia, and sinus tachycardia, as well as various
            degrees of AV block, are seen on the ECG. These usually last only a few seconds and resolve without intervention.
            						
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>
            							Note: Flushing may occur along with a feeling of warmth as drug is injected.
            						
         </li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>